Table 3.
Hormonal analyses of adult male lymphoma survivors according to testosterone group, with subdivisions according to the availability of two sample, at diagnosis and follow-up
|
Survivors with “low normal TT” (extended hormonal assessment) N 60 |
Survivors with “high normal TT” (no extended hormonal analysis) N 83 |
||||||
|---|---|---|---|---|---|---|---|
| 20 survivors with two samples (cryopreservation at diagnosis + VitalityCheck) | 40 with one sample (VitalityCheck) | 30 survivors with two samples (cryopreservation at diagnosis + VitalityObs) | |||||
| Diagnosis | FU2 | FU2 | Diagnosis | ||||
| Median (perc) | Median (perc) | % change | Median (perc) | % difference between FU2-20 to FU-40* | Median (perc) | % difference between diagnosis samples | |
| TT, IA, nmol/l | 14.2 (8.1–21.3) | 10.6 (8.3–14.6) | 21.1%↓* (5.2–34.3) | 10.4 (6.8–16.3) | 5.1%↓ (− 4.7–19.8) | 15.4 (11.3–28.9) | 10.5% (− 12.6–39.7) |
| cFT, IA, pmol/l | 339 (202–516) | 279 (171–368) | 21.1%↓* (5.2–34.3) | 208 (136–323) | 19.1%↓* (4.3–31.3) | 350 (196–596) | 1.4% (− 20.2–28.9) |
| SHBG, nmol/l | 24.5 (13.9–35.2) | 22.2 (15.5–35.4) | 4.4%↓ (− 18.2–11.6) | 30.3 (18.4–52.5) | 34.4%↑* (10.6–63.3) | 30.0 (17.8–51.6) | 23.4%* (0.4–51.8) |
| LH, IU/l | 5.6 (2.1–9.6) | 4.4 (2.0–10.7) | 13.4%↓ (− 38.2–21.5) | 4.2 (2.3–9.5) | 3.9%↑ (− 23.4–40.9) | 3.9 (1.9–7.3) | 22.7% (− 40.6–0.7) |
| TT/LH ratio | 2.7 (1.2–5.3) | 2.8 (1.3–4.5) | 11.1%↓ (− 39.8–31.4) | 2.3 (1.0–5.2) | 10.8%↑ (− 33.1–18.8) | 4.4 (1.6) 1.35 (0.46) | 42.9%* (3.9–96.7) |
| cFT/LH ratio | 0.06 (0.03–0.16) | 0.07 (0.03–0.11) | 4.2%↓ (− 41.0–34.2) | 0.05 (0.02–0.11) | 24.9%↑ (− 45.4–3.3) | 0.09 (0.05–0.14) | 34.1% (− 2.1–83.5) |
N, number; FU1, at VitalityObs; FU2, at VitalityCheck; TT, total testosterone; FT, free testosterone; SHBG, sexual hormone binding globulin; LH, luteinizing hormone; CI, confidence interval; FU2, follow-up 2.
*Significant changes and differences.